HC Wainwright & Co. Maintains Buy on Sernova Biotherapeutics, Lowers Price Target to C$1

HC Wainwright & Co. analyst Joseph Pantginis maintains Sernova Biotherapeutics (TSX:SVA) with a Buy and lowers the price target from C$6 to C$1.